UroGen Pharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for UroGen Pharma Ltd. (URGN) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-126.87-102.24-109.78-110.82-128.48-105.15-75.66
Depreciation & Amortization1.191.711.821.772.480.750.42
Stock Based Compensation13.119.3410.5823.1128.030.000.00
Change in Working Capital4.933.34-5.18-14.28-11.932.537.16
Change in Accounts Receivable-4.86-2.74-0.99-4.67-7.050.000.00
Change in Inventory-3.55-1.35-0.36-2.87-1.960.000.00
Change in Accounts Payable10.894.160.282.00-1.250.000.00
Change in Other Working Capital1.861.01-4.29-1.181.170.000.00
Other Operating Activities13.771.0113.75-1.1829.2029.060.00
Net Cash from Operating Activities-96.77-76.38-87.56-84.89-105.89-71.02-37.33
Investing Activities
Capital Expenditures-0.30-0.19-0.25-0.751.220.33-0.56
Purchases of Investments-20.32-49.831.31-51.9094.450.000.00
Sales/Maturities of Investments107.7149.071.3156.7294.45-145.2735.90
Other Investing Activities0.000.000.000.000.000.00-0.05
Net Cash from Investing Activities-20.61-0.951.064.0793.24-145.5935.29
Financing Activities
Debt Repayment24.490.000.000.000.000.000.00
Common Stock Issued151.4967.361.51-0.1415.85161.6664.24
Other Financing Activities18.6448.70-0.1672.26-0.07-0.08-0.22
Net Cash from Financing Activities194.62116.9397.1372.3216.53165.2566.42
Summary
Net Change in Cash77.2439.6010.64-8.503.88-51.3664.37
Cash at Beginning of Period95.8256.2245.5954.0950.21101.5737.20
Cash at End of Period173.0695.8256.2245.5954.0950.21101.57
Free Cash Flow-97.06-76.57-87.81-85.64-107.10-71.34-37.89